STRO

8.6001.38%
HG

Hans-Peter Gerber

Chief Scientific Officer

Dr. Hans-Peter Gerber, Ph.D., serves as Chief Scientific Officer of Sutro Biopharma, Inc. since September 18, 2023. He served as President and Chief Scientific Officer at Maverick Therapeutics, Inc. Dr. Gerber has drug discovery and development experience, with extensive scientific background and expertise in ADCs, targeted oncology and novel biotherapeutic platforms. Dr. Gerber began his Biotech career at Genentech in the Department of Molecular Oncology, followed by various management roles at Seattle Genetics and Pfizer. He has a strong track record in leading cross-functional teams, innovative discovery and translational medicine and contributions to IND filings and BLA submissions. Prior to joining Sutro, Dr. Gerber served as Chief Scientific Officer at Codeable Therapeutics, an ADC startup company focusing on the development of next generation ADCs that induce immunogenic cell death. From April 2018 to March 2022, Dr. Gerber served as Chief Scientific Officer and Senior Vice President of 3T Biosciences, Inc. Previously, he held executive roles Maverick Therapeutics. He has also served as an advisor for various Biotech startups, VCs and Pharma companies and is currently a Board member at Athebio AG and Chairman of the Board at T-CURX. With over 100 peer-reviewed publications and 100 issued patents, he has an impressive record of high scientific achievement. He received an MS in Biochemistry and a PhD in Molecular Biology from the University of Zurich, Switzerland.

Positions